News

EMA Recommends Oxbryta® for Sickle Cell Anaemia

EMA Recommends Oxbryta® for Sickle Cell Anaemia

The Committee for Medicinal Products for Human Use at the EMA adopted a positive opinion recommending marketing authorization for Oxbryta® (voxelotor) for the treatment of haemolytic anaemia due to sickle cell disease in patients 12 years of age and older

read more...